CAELUS PHARMACEUTICALS
Live / Registered — Registered — partial invalidation of extension of protection (as of 07 Apr 2025)
What this means for you
Registered since 04 Dec 2018. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79222834
- Registration number
- 5619593
- Mark type
- Stylized text
- Filed
- 01 Jun 2017
- Published for opposition
- 18 Sept 2018
- Registered
- 04 Dec 2018
- Attorney of record
- Roberto Ledesma
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products for treating cardiometabolic disorders; dietetic foodstuffs adapted for medical use and dietetic substances, namely, dietetic foods adapted for medical use; food supplements for human beings; medical preparations and articles for the treatment of cardiometabolic disorders; [ diagnostic preparations for medical use; pharmaceutical products and natural medicines, both for the treatment of cardiometabolic disorders; vaccines; ] pharmaceutical preparations, namely, medicines [ and vaccines, ] for the prevention of diabetes mellitus [ , Crohn's disease and ulcerative colitis disease ] ; pharmaceutical preparations, namely, medicines for the treatment of diabetes mellitus, [ Crohn's disease, ulcerative colitis disease ] and metabolic syndrome being insulin resistance; dietetic nutritional food additives for medical purposes in the nature of natural food extracts derived from gut-microbiota and dietetic preparations, namely, dietary supplements; dietary food preparations, namely, dietetic nutritional food additives for medical purposes in the nature of natural food extracts derived from gut-microbiota and dietetic substances in the nature of dietary supplements for the prevention of diabetes mellitus [ , Crohn's disease and ulcerative colitis disease ] ; dietary food preparations, namely, dietetic nutritional food additives for medical purposes in the nature of natural food extracts derived from gut-microbiota and dietetic substances in the nature of dietary supplements for the treatment of diabetes mellitus [ , Crohn's disease, ulcerative colitis disease ] and metabolic syndrome being insulin resistance; medical preparations, namely, cultures of microorganisms for medical use, and bacterial preparations for medical use [ ; chemicals for the diagnosis of diabetes mellitus, Crohn's disease and ulcerative colitis disease; vaccine preparations for human use ]
- Class 010 — Medical apparatus: [ Medical apparatus and instruments, namely, for use in treating cardiovascular disease or diabetes, for monitoring vital signs, blood sugar levels, AGE-levels in the skin and gut/skin microbiota composition; Medical diagnostic, testing and monitoring equipment, namely, medical diagnostic equipment for detecting and monitoring blood sugar levels, AGEs and microbiome composition; testing apparatus for medical use, namely, medical devices for testing blood glucose, microbiome composition in gut and on the skin, testing AGE-levels, and for testing the levels of butyrate in breath analysis; measuring devices for medical use, namely, medical device for measuring glucose, insulin, butyrate, propionate, gut and skin microbiome; testing apparatus for medical use, namely, blood testing apparatus, apparatus for analyzing feces or respiratory gas, medical measuring devices for medical use, namely, devices for measuring microorganisms or gas; medical test kits for home monitoring of diabetes ]
Owner
- Caelus Pharmaceuticals B.V., Zegveld, NL
- Caelus Pharmaceuticals B.V., NL
- Caelus Pharmaceuticals B.V., NL
Prosecution history
- 10 Sept 2026 — Further Decision Processed by IB
- 08 Jul 2026 — GENERIC MADRID TRANSACTION SENT TO IB
- 08 Jul 2026 — GENERIC MADRID TRANSACTION CREATED
- 08 Jul 2026 — INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
- 07 Dec 2025 — PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
- 07 Apr 2025 — NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
- 07 Apr 2025 — REGISTERED - PARTIAL SEC 71 ACCEPTED
- 07 Apr 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 14 Nov 2024 — TEAS SECTION 71 RECEIVED
- 30 Dec 2023 — NEW REPRESENTATIVE AT IB RECEIVED
- 04 Dec 2023 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 05 Apr 2019 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 18 Mar 2019 — FINAL DISPOSITION NOTICE SENT TO IB
- 18 Mar 2019 — FINAL DISPOSITION PROCESSED
- 04 Mar 2019 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB